SOPHIA ANTIPOLIS, France – March 22, 2023 │The Quarterly Report for the Q4 2022 Therapeutic mRNA Patent Monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. Let’s focus on one of the most dynamic segments. KnowMade has developed expertise in the field of therapeutic[…]
SOPHIA ANTIPOLIS, France – March 16, 2023 │ Q4 2022 Therapeutic mRNA Patent Monitor (covering mRNA design, mRNA delivery, manufacturing, storage, mRNA-based vaccines, and mRNA-based therapeutics) quarterly report is out! Let’s focus on one interesting aspect of delivery innovation. KnowMade has developed expertise in therapeutics mRNA that allows a picture from three angles of this[…]
Moderna and Merck join forces to advance mRNA therapeutics in cancer treatment SOPHIA ANTIPOLIS, France – March 03, 2023 │mRNA therapeutics against cancer are an area of strong R&D activity, especially since the efficient use of mRNA vaccines to fight the SARS-CoV-2 pandemic. On the other hand, although the number of clinical trials is increasing,[…]
SOPHIA ANTIPOLIS, France – January 13, 2023 │ OriCiro’s synthetic biology and enzyme technologies will support Moderna’s expanding portfolio of mRNA therapeutics and vaccines. Moderna press release here. Moderna is a major and active company in the field of therapeutic mRNA Active development of mRNA technologies for vaccines and therapies Messenger RNAs are under active[…]